Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flavored dachengqi decoction is a modified Traditional Chinese Medicine (TCM) herbal formula based on the classic Da Cheng Qi Tang. Developed and utilized by the Linping Hospital of Integrated Traditional Chinese and Western Medicine in Hangzhou, China, it is primarily indicated for the management of colorectal polyps, particularly for preventing recurrence following endoscopic resection. The formula typically consists of a base of Rhubarb (*Rheum palmatum*), Magnolia bark (*Magnolia officinalis*), Immature Bitter Orange (*Citrus aurantium*), and Mirabilite (Glauber's salt), with additional "flavoring" herbs added to clear heat, detoxify, and resolve blood stasis. Its mechanism of action involves promoting gastrointestinal motility, regulating the intestinal microenvironment, and exerting anti-inflammatory and pro-apoptotic effects on polypoid tissues by modulating cytokines such as TNF-alpha and COX-2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flavored dachengqi decoction.